www.cullgen.com/Healthcare / BioTech & PharmaFounded: 2018Funding to Date: $116MM
Cullgen, founded in 2018, is a biopharmaceutical company that develops new chemical entities (NCEs) designed to treat diseases that lack effective therapeutic approaches. Using its proprietary uSMITE™ platform, the company expands on the drug design paradigm aiming to target proteins that are typically resistant to treatments for selective destruction. Cullgen has produced several highly potent, selective, and bioavailable targeted protein degrader compounds. Cullgen is headquartered in San Diego, California.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cullgen.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.